Decline in cognitive function over 18 months in healthy older adults with high amyloid-β

Journal of Alzheimer's Disease

Volumn 34, Issue 4, 2013, Pages 861-871

  Ellis, Kathryn A ^a,b   Lim, Yen Ying ^a   Harrington, Karra ^a   Ames, David ^a,b   Bush, Ashley I ^a   Darby, David ^a   Martins, Ralph N ^c   Masters, Colin L ^a   Rowe, Christopher C ^a,d   Savage, Greg ^e   Szoeke, Cassandra ^a,b   Villemagne, Victor L ^a,d   Maruff, Paul ^a,f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^c EDITH COWAN UNIVERSITY   (Australia)

^d AUSTIN HEALTH   (Australia)

^e MACQUARIE UNIVERSITY   (Australia)

^f Scientific Division   (Australia)

Author keywords

Alzheimer's disease; amyloid ; apolipoprotein E 4; cognitive change; cognitive neuropsychology; healthy older adults

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4;

AGED; ALLELE; ARTICLE; ATTENTION; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DETERIORATION; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RECALL; SHORT TERM MEMORY; VISUAL MEMORY;

EID: 84873392475     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122170     Document Type: Article

References (51)

1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi WZ, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65, 1509-1517.
2. Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) 11C-PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, 446-452. (Pubitemid 44214969)
3. Lim YY, Ellis KA, Harrington K, Kamer A, Pietrzak RH, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Ames D, Maruff P, Group Research AIBL (2013) Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease. Neuropsychology, in press.
4. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ, AV45-A11 Study, Group (2012) Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology 79, 1636-1644.
5. Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131, 665-680. (Pubitemid 351294719)
6. Lim YY, Ellis KA, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P, Group Research AIBL (2012) Aβ amyloid, cognition and APOE genotype in the preclinical stages of Alzheimer's disease. Alzheimers Dement, doi: 10.1016/j.jalz.2012.07.004
7. Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML, Ivnik RJ, Preboske GM, Roberts R, Geda YE, Boeve BF, Knopman DS, Petersen RC, Jack CR (2012) APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology 78, 232-240.
8. RodrigueKM,KennedyKM,DevousMD,Rieck JR, Hebrank AC, Diaz-Arrastia R, Mathews D, Park DC (2012) β-amyloid burden in healthy aging: Regional distribution and cognitive consequences. Neurology 78, 387-395.
9. Pike KE, Ellis KA, Villemagne VL, Good NM, Chetelat G, Ames D, SzoekeC,Laws SM,Verdile G, Martins RN, Masters C, RoweCC(2011) Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia 49, 2384-2390.
10. Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P, Group Research AIBL (2012) Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 79, 1645-1652.
11. Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL, Group Research AIBL (2012) Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: A voxelwise PiB-PET longitudinal study. Brain 135(pt 7), 2126-2139.
12. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69, 181-192.
13. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC (2008) Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46, 1688-1697.
14. Lim YY, Pietrzak RH, Ellis KA, Jaeger J, Harrington K, Ashwood T, Szoeke C, Martins RN, Bush AI, Masters CL, Rowe CC, Villemagne VL, Ames D, Darby D, Maruff P (2013) Rapid decline in episodic memory in healthy older adults with high amyloid-β. J Alzheimers Dis 33(3), doi: 10.3233/JAD- 2012-121516
15. Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JQ, Aisen P, Petersen RC, Schuff N,Weiner MF, Initiative AsDN (2012) CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 22, 1993-2004.
16. Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe C, Group Research AIBL (2012) Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 78, 477-484.
17. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, Van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ, Alzheimer's Disease Cooperative Study (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61, 59-66. (Pubitemid 38067415)
18. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M (2007) A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64, 1323-1329. (Pubitemid 47403089)
19. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D, Group Research AIBL (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21, 672-687.
20. Morris JC (1983) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414.
21. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins RM, Ames CL, Villemagne D, V (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
22. Lim YY, Ellis KA, Harrington K, Ames D, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Darby D, Maruff P, Group Research AIBL (2012) Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. J Clin Exp Neuropsyc 34, 345-358.
23. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state:Apractical method for grading cognitive state of patients for the clinician. J Psychiat Res 12, 189-198.
24. Wechsler D (2001) Wechsler Test of Adult Reading: Examiner's manual, The Psychological Corporation, San Antonio, TX.
25. Snaith RP, Zigmond AS (1986) The hospital anxiety and depression scale. Brit Med J 292, 344.
26. WechslerD(1997)Wechsler Adult Intelligence Scale (WAISIII), Psychological Corporation, San Antonio, TX.
27. Meyers JE, Meyers KR (1995) Rey Complex Figure Test and Recognition Trial., Professional Manual: Psychological Assessment Resource, Inc.
28. Saxton J, Ratcliff G, Munro CA, Coffey EC, Becker JT, Fried L,Kuller L (2000) Normative data on the Boston Naming Test and two equivalent 30-item short forms. Clin Neuropsychol 14, 526-534.
29. Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California Verbal Learning Test - Second Edition (CVLT-II), The Psychological Corporation, San Antonio, TX.
30. Wechsler D (1945) A standardized memory scale for clinical use. J Psychol 19, 87-95.
31. Delis DC, Kaplan E, Kramer JH (2001) The Delis-Kaplan Executive Function System (D-KEFS). Psychological Corporation, San Antonio, TX.
32. Strauss E, Sherman EMS, Spreen O (2006) A compendium of neuropsychological tests: Administration, norms and commentary, Oxford University Press, New York.
33. Cohen J (1992) A power primer. Psychol Bull 112, 155-159.
34. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194. (Pubitemid 39222988)
35. Nordlund A, Rolstad S, Hellström P, Sjögren M, Hansen S, Wallin A (2005) The Goteborg MCI study: Mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychology 76, 1485-1490. (Pubitemid 41531690)
36. Humpel C (2011) Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp Gerontol 46, 225-232.
37. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB (2003) Vascular cognitive impairment. Lancet Neurol 2, 89-98. (Pubitemid 37443329)
38. Yates PA, Sirisriro R,Villemagne VL, Farquharson S, Masters CL, Rowe CC, Group Research AIBL (2011) Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease. Neurology 77, 48-54.
39. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DEC, Snyder CH, Alexander GE, Rademakers R, Reiman EM (2009) Longitudinal modeling of age-related memory decline and the APOE ε4 effect. New Engl J Med 361, 255-263.
40. Schiepers OJG, Harris SE, Gow AJ, Pattie A, Brett CE, Starr JM, Deary IJ (2012) APOE ε4 status predicts age-related cognitive decline in the ninth decade: Longitudinal follow-up of the Lothian Birth Cohort 1921. Mol Psychiatr 17, 315-324.
41. Hofer SM, Christensen H, Mackinnon AJ, Korten AE, Jorm AF, Henderson AS, Easteal S (2002) Change in cognitive functioning associated with APOE genotype in a community sample of older adults. Psychol Aging 17, 194-208. (Pubitemid 34568636)
42. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) β-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844. (Pubitemid 350033975)
43. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative (2008) Episodic memory loss is related to hippocampal-mediated β-amyloid deposition in elderly subjects. Brain 132, 1310-1323.
44. Storandt M, Mintun MA, Head D, Morris JC (2009) Cognitive decline and brain volume loss as signatures of cerebral amyloid-β peptide deposition identified with Pittsburgh Compound B: Cognitive decline associated with Aβ deposition. Arch Neurol 66, 1476-1481.
45. Rentz DM, Locascio JJ, Becker JA,Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA (2010) Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67, 353-364.
46. Darby D, Brodtmann A, Pietrzak RH, Fredrickson J, Woodward M, Villemagne V, Fredrickson A, Maruff P, Rowe C (2011) Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. J Alzheimers Dis 27, 627-637.
47. Darby D, Pietrzak RH, Fredrickson J,Woodward M, Moore L, Fredrickson A, Sach J, Maruff P (2012) Intra-individual cognitive decline using a brief computerized cognitive screening test. Alzheimers Dement 8, 95-104.
48. Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters C, Rowe CC, Group Research AIBL (2010) Independent contribution of temporal β-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 134, 798-807.
49. Small GW, Siddarth P, Kepe V, Ercoli LM, Burggren AC, Bookheimer SY, Miller KJ, Kim J, Lavretsky H, Huang SC, Barrio JR (2012) Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 69, 215-222.
50. Christensen DD (2007) Changing the course of Alzheimer's disease: Anti-amyloid disease-modifying treatments on the horizon. J Clin Psychiat 9, 32-41. (Pubitemid 46280276)
51. Aisen PS (2005) The development of anti-amyloid therapy of Alzheimer's disease: From secretase modulators to polymerisation inhibitors. CNS Drugs 19, 989-996. (Pubitemid 41775990)